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https://doi.org/10.101The presence of chromosomal gains other than trisomy 12 suggesting a hyperdiploid
karyotype is extremely rare in chronic lymphocytic leukemia (CLL) and is associated
with a dismal prognosis. However, the genetic mechanisms and mutational background
of these patients have not been fully explored. To improve our understanding of the
genetic underpinnings of this subgroup of CLL, seven CLL patients with several chro-
mosomal gains were sequenced using a next-generation sequencing (NGS)-targeted
approach. The mutational status of 54 genes was evaluated using a custom-designed
gene panel including recurrent mutated genes observed in CLL and widely associated
with CLL pathogenesis. A total of 21 mutations were detected; TP53 (42.8%), ATM
(28.5%), SF3B1 (28.5%), and BRAF (28.5%) were the most recurrently mutated genes.
Of these mutations, 61.9% were detected in genes previously associated with a poor
prognosis in CLL. Interestingly, five of the seven patients exhibited alterations in TP53
or ATM (deletion and/or mutation), genes involved in the DNA damage response (DDR),
which could be related to a high genetic instability in this subgroup of patients. In con-
clusion, CLL patients with several chromosomal gains exhibit high genetic instability,
with mutations in CLL driver genes and high-risk genetic alterations involving ATM
and/or TP53 genes. © 2019 Published by Elsevier Inc. on behalf of ISEH – Society for
Hematology and Stem Cells.Hyperdiploidy is a common cytogenetic abnormality in B
acute lymphoblastic leukemia (B-ALL) and multiple mye-
loma (MM) and is associated with a good disease course in
both hematological malignancies [1,2]. By contrast, hyperdi-
ploidy is a very rare event in chronic lymphocytic leukemia
(CLL), occurring at a frequency lower than 1% and being
associated with a poor prognosis [3−5]. Most patients with: Jesus-Marıa Hernandez-Rivas, IBMCC, CIC Uni-
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6/j.exphem.2019.02.003hyperdiploidy required a significantly shorter time to first
treatment and had shorter overall survival [4].
It has been suggested that hyperdiploidy is explained by
the presence of genomic instability, which could be associ-
ated with TP53 disruption [6]. In fact, deletion of 17p (17p
−) is the most frequent cytogenetic abnormality concurring
with hyperdiploidy in CLL [4]. The implementation of next-
generation sequencing (NGS) has provided new insights into
CLL complexity, identifying a growing list of putative driver
genes that underlie the heterogeneity in CLL [7,8]. However,
little is known about the genetic background underlying
hyperdiploidy. Therefore, in this study, we analyzed the
mutational status of a panel of CLL mutated genes in a sub-
set of well-characterized CLL patients with hyperdiploidy toHematology and Stem Cells.
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documented subgroup of CLLs.Methods
A total of seven patients with hyperdiploidy were included in the
sequencing study. Clinical data were previously reported [4]. The
main clinical and biological features of each patient are summarized
in Supplementary Table E1 (online only, available at www.exphem.
org). The study was approved by the ethics committee of Hospital
Universitario de Salamanca. For all samples, written informed con-
sent approved by the ethics committees of the respective institutions
were available in accordance with the Declaration of Helsinki.
Hyperdiploidy was considered when a gain of at least three of the
five fluorescence in situ hybridization (FISH) probes used (11q22/
ATM, 12q13, 13q34, 14q34/IGH, and 17p13/TP53) was observed,
as previously described [4]. Five samples were obtained at the time
of diagnosis (P3−P7), with the exception of two analyzed at the
time of progression (P1 and P2). Genomic DNA was isolated from
peripheral blood and/or bone marrow samples using a QIAamp
DNA Mini Kit according to the manufacturer’s protocol (Qiagen,
Valencia, CA, USA). DNA concentration was measured with a
Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA, USA).
Agilent SureDesign was used to perform a design with 8,951
probes (416.393 kbp) targeting 682 regions of a panel of 54 genes
previously reported as mutated in CLL or involved in the disease
pathogenesis (Supplementary Table E2, online only, available at
www.exphem.org) [7,8]. Sequence data generated by the MiSeq
platform were analyzed by an in-house bioinformatic pipeline
mapping reads to the Reference Human Genome (hg19). The
Burrows−Wheeler Aligner (BWA) and Genome Analysis Tool Kit
(GATK) were used for variant calling of single-nucleotide variants
(SNVs) and short insertions/deletions (InDels) [9,10]. A mean depth
of 284 reads/base within the regions of interest was obtained, with
95% of regions sufficiently covered (>100 £). Supplementary TableTable 1. Summary of the mutations identified by NGS in CLL patients with hyperdiploidy.





1 ATM NM_000051 c.C1810T p.P604S
1 BRAF NM_004333 c.A1781G p.D594G
2 MGA NM_001080541 c.C6217T p.Q2073X
2 TP53 NM_000546 c.451C>G p.P190A
2 RPS15 NM_001018 c.C413T p.S138F
2 SF3B1 NM_012433 c.A1997C p.K666T
2 SF3B1 NM_012433 c.A1996C p.K666Q
2 NOTCH1 NM_017617 c.7541_7542del p.P2514fs
3 TP53 NM_000546 c.919+1G>T —
3 PCDH10 NM_032961 c.A2914G p.N972D
5 FUBP1 NM_003902 c.A1040G p.Q347R
5 ATM NM_000051 c.G8440T p.E2814X
5 ATM NM_000051 c.G8773A p.G2925S
5 BRAF NM_004333 c.G1780A p.D594N
6 IGLL5 NM_001178126 c.C85G p.L29V
6 IGLL5 NM_001256296 c.G21A p.W7X
6 IGLL5 NM_001178126 c.A146C p.D49A
6 KLHL6 NM_130446 c.T269C p.L90P
6 KLHL6 NM_130446 c.C268T p.L90F
7 TP53 NM_000546 c.T613G p.Y205D
7 SF3B1 NM_012433 c.G1874T p.R625LE3 (online only, available at www.exphem.org) outlines the cover-
age data for each sample. Variants were then filtered according to
the severity of the consequence, to accept variants leading to an
amino acid change in the protein sequence (missense, nonsense,
frameshift) and those in the splice site. Minor allelic frequencies
(MAFs) were consulted in the Exome Variant Server, 1000
Genomes Browser, and exome aggregation consortium (ExAC)
databases, removing those with a MAF >1%. All accepted muta-
tions were reviewed individually with Integrative Genomics Viewer
(IGV, Broad Institute, Cambridge, MA, USA) software.
In line with the sequencing approach explained previ-
ously, the mutational status of a cohort of unselected CLL
patients without hyperdiploidy was also assessed (n = 50).
Clinical and biological data from this control group are sum-
marized in Supplementary Table E4 (online only, available
at www.exphem.org). Samples were sequenced at the
moment of diagnosis or pretreatment.
Statistical analyses were performed using IBM SPSS for Win-
dows, Version 22.0 (IBM Corp., Armonk, NY, USA). The x2 test
was used to assess associations between categorical variables; con-
tinuous variables were analyzed with the Mann−Whitney U test.
Results were considered statistically significant at P values<0.05.Results and Discussion
Patients with hyperdiploidy had a higher percentage of
CLL driver mutations
Within patients with hyperdiploidy, a total of 21 mutations
were detected: 18 missense, 3 stop nonsense, 1 frameshift,
and 1 splicing (Table 1; Supplementary Table E5, online
only, available at www.exphem.org). The most frequently
mutated genes were TP53 (3/7, 42.8%), ATM (2/7, 28.5%),





54.05 74 COSM22499 Yes
30.63 161 COSM467 Yes
33.85 130 — —
33.33 111 COSM99680 No
42.55 94 — —
4.67 107 COSM131556 Yes
11.82 110 COSM132950 Yes
35.8 243 COSM12774 Yes
75.21 117 COSM3378337 No
45.37 205 — —
30.54 167 — —
62.07 58 — —
20 145 — —
13.73 153 COSM27639 yes
13.56 317 — —
13.13 297 COSM3357309 yes
11.9 294 — —
12.84 148 — —
12 150 — —
92.5 200 — —
40.76 157 COSM110695 yes
Figure 1. (A) Molecular background in chronic lymphocytic leukemia (CLL) patients with chromosomal gains. Mutations and chromosomal
alteration information are shown across the list of genes or fluorescence in situ hybridization (FISH) abnormalities (rows) for seven CLL samples
that underwent next-generation sequencing (columns). The number of chromosomes with the FISH panel (percentage of cells with the gain) was
detailed in the last row for each case. (B) Exemplary screenshot from the Integrative Genomics Viewer revealing the reads obtained within chro-
mosome region chr2: 198267343−198267383 in patient ID3. Two SF3B1 sequence variants are depicted that are located on distinct sequencing
reads, indicating the presence of two individual mutational clones in this patient.
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RPS15, MGA, PDCH10, FUBP1, IGLL5, and KLHL6,
which were mutated in one patient each (1/7, 14.3%). The
incidence of mutations of these CLL drivers was higher in
this cohort of CLL with chromosomal gains than in the
reported CLL series [7,8,11,12]. Specifically, BRAF muta-
tions were approximately 10-fold more frequent in hyperdi-
ploid CLLs than in other cohorts [7,8,13]. Of note, these
2 BRAF mutations were located in the same codon
(p.D594N y p.D594G) in two cases, not involving the
canonical hotspot (V600E) seen in other malignancies
[14,15]. Sixteen of the total of 21 mutations were previ-
ously reported in the Catalogue of Somatic Mutations in
Cancer (COSMIC) or in other CLL sequencing studies
[7,8] (Supplementary Table E5).
It should be noted that 61.9% of the mutations (13/21)
were detected in genes previously associated with a poor
prognosis in CLL [7,8], such as ATM (n = 3), TP53 (n = 3),
SF3B1 (n = 3), BRAF (n = 2), NOTCH1 (n = 1), and RPS15
(n = 1). By contrast, none of the patients exhibited MYD88
mutations, which have been associated with a good prog-
nosis in CLL [16].
Most of the patients (6/7, 85.7%) had more than 2
CLL driver mutations within the set of genes analyzed
in our study. Patient P2, who was analyzed at the time
of CLL progression, had the largest number of muta-
tions: 6. Of note, this patient exhibited 2 different
mutations on SF3B1 affecting the same codon but in
different clones (Figure 1B). This clearly illustrates
intratumoral genetic heterogeneity, which could be a
reflex of the presence of genomic instability [7,17].
Most CLL patients with chromosomal gains exhibited
genetic alterations in genes involved in the DNA
damage response
Interestingly, 71.4% of the patients (5/7) exhibited
alterations in TP53 or ATM (deletion and/or mutation).
Mutational inactivation of these genes involved in
DDR mechanisms is an established hallmark of CLL
and is associated with high genomic instability [18,19].
Three patients had TP53 alterations: only mutation
(P7) and mutation plus 17p− (P2 and P3). One of the
patients (P2) also had a mutation on RPS15, a gene
recently associated with TP53 alterations [20]. Of note,
two TP53-mutated patients (P2 and P7) also had
SF3B1 mutations, which have been associated with an
altered DDR [21,22]. Two patients harbored ATM alter-
ations: only mutation (P1) and mutation plus 11q−
(P5). Both patients also had BRAF mutations, suggest-
ing that the combination of these two mutated genes
(ATM + BRAF) could be related to hyperdiploid karyo-
type. Normal BCR and pre-BCR signaling occurs
through BRAF, which activates ERK proteins [22],
resulting in the deregulation of a set of genes. BRAF
mutations target amino acids located in the P-loop ofthe kinase, resulting in a weaker activation than the
canonical V600E [22].
Comparison of the group of CLL patients with hyperdi-
ploidy and the cohort of CLL patients without hyperdi-
ploidy revealed that the frequency of mutations in TP53 or
ATM was significantly higher in patients with hyperdi-
ploidy (72% vs. 12%, P = 0.002). Mutations in these genes
could impair DDR mechanisms, which could result in
genetic instability in CLL patients [21,23]. Notably, a
larger number of mutations were observed in CLL patients
with hyperdiploidy than in those without this genetic back-
ground (median number of mutations = 4 vs. 1, P = 0.001).
In addition, within patients with hyperdiploidy, the percent-
age of cases with more than one mutated gene was higher
than that in the control group (86% vs. 20%, P = 0.001).
Supplementary Table E5 lists the mutations in the CLL
patients sequenced in this study. Functional studies should
be performed to confirm an impairment of the DDR in
CLL primary cells in patients with hyperdiploidy.
In conclusion, the presence of mutations in CLL driver
genes and high-risk genetic alterations involving the DDR
pathway is greatly enriched in CLL patients with several
chromosomal gains, suggesting that genomic instability
could be a hallmark of hyperdiploidy in CLL.
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